Robert Bissonnette, MD, Innovaderm Research, discusses JNJ-2113, an investigational, oral peptide inhibitor for patients with psoriasis. Dr Bissonnette notes that JNJ-2113 is the first oral peptide against IL-23 to demonstrate improvements in immune-mediated disease.